Home › Degenerative Nerve Diseases › California › San Francisco
Degenerative Nerve Diseases clinical trials in San Francisco, CA
3 studies for Degenerative Nerve Diseases are looking for participants at sites in and around San Francisco (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Parkinson Progression Marker Initiative Online (PPMI Online)
RecruitingObservational studyHealthy volunteers welcome
- UCSF Movement Disorders and Neuromodulation Center (MDNC), San Francisco
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
RecruitingObservational studyHealthy volunteers welcome
- University of California, San Francisco, San Francisco
Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance
RecruitingHealthy volunteers welcome
- San Francisco Research Institute, San Francisco
About Degenerative Nerve Diseases
Degenerative nerve diseases, or neurodegenerative diseases, are disorders that destroy cells in your nervous system. Learn about the types and treatments.
More about Degenerative Nerve Diseases on MedlinePlus
Degenerative Nerve Diseases trials in other cities
- Philadelphia, PA6 studies
- Orlando, FL5 studies
- Tampa, FL5 studies
- Boston, MA5 studies
- Scottsdale, AZ4 studies
- San Diego, CA4 studies
- Atlanta, GA4 studies
- Baltimore, MD3 studies
- Los Angeles, CA3 studies
- Farmington Hills, MI3 studies
- Austin, TX3 studies
- West Palm Beach, FL3 studies
Other studies in San Francisco
- Prostate Cancer44 studies
- Breast Cancer40 studies
- Cancer (all types)38 studies
- Non-Small Cell Lung Cancer37 studies
- Heart Failure29 studies
- Metastatic Cancer25 studies
- Lung Cancer23 studies
- Melanoma21 studies
- Ovarian Cancer20 studies
- Cardiovascular Disease20 studies
- Pancreatic Cancer19 studies
- Glioblastoma19 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.